Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Aerts

Showing results (291-300 of 361) with videos related to

Pageof 37
Sort By:
Blood|September 13, 2003
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic interventionRolf G Boot, Marri Verhoek, Maaike de Fost, et al.
ACS Central Science|August 5, 2017
1,6-Cyclophellitol Cyclosulfates: A New Class of Irreversible Glycosidase InhibitorMarta Artola, Liang Wu, Maria J Ferraz, et al.
ACS Central Science|July 11, 2017
Correction to "Detection of Active Mammalian GH31 α-Glucosidases in Health and Disease Using In-Class, Broad-Spectrum Activity-Based Probes"Jianbing Jiang, Chi-Lin Kuo, Liang Wu, et al.
Plos One|July 9, 2011
Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff diseaseKaren M Ashe, Dinesh Bangari, Lingyun Li, et al.
Biochimica Et Biophysica Acta|May 18, 2010
Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry diseaseS M Rombach, N Dekker, M G Bouwman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trialF Barlesi, A Scherpereel, V Gorbunova, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2026
Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in bloodKarlijn de Joode, Hayri E Balcioglu, Mandy van Brakel, et al.
Frontiers in Plant Science|July 7, 2017
Human Alpha Galactosidases Transiently Produced in <i>Nicotiana benthamiana</i> Leaves: New Insights in Substrate Specificities with Relevance for Fabry DiseaseKassiani Kytidou, Thomas J M Beenakker, Lotte B Westerhof, et al.
BMC Pulmonary Medicine|March 23, 2018
IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomesAdrian Egli, Jyotshna Mandal, Desiree M Schumann, et al.
Chemical Science|November 30, 2023
<i>Trans</i>-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump-hole strategyAlexandra Males, Ken Kok, Alba Nin-Hill, et al.
Pageof 37

Showing results (291-300 of 361) with videos related to

Sort By:
Pageof 37
Blood|September 13, 2003
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic interventionRolf G Boot, Marri Verhoek, Maaike de Fost, et al.
ACS Central Science|August 5, 2017
1,6-Cyclophellitol Cyclosulfates: A New Class of Irreversible Glycosidase InhibitorMarta Artola, Liang Wu, Maria J Ferraz, et al.
ACS Central Science|July 11, 2017
Correction to "Detection of Active Mammalian GH31 α-Glucosidases in Health and Disease Using In-Class, Broad-Spectrum Activity-Based Probes"Jianbing Jiang, Chi-Lin Kuo, Liang Wu, et al.
Plos One|July 9, 2011
Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff diseaseKaren M Ashe, Dinesh Bangari, Lingyun Li, et al.
Biochimica Et Biophysica Acta|May 18, 2010
Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry diseaseS M Rombach, N Dekker, M G Bouwman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trialF Barlesi, A Scherpereel, V Gorbunova, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 11, 2026
Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in bloodKarlijn de Joode, Hayri E Balcioglu, Mandy van Brakel, et al.
Frontiers in Plant Science|July 7, 2017
Human Alpha Galactosidases Transiently Produced in <i>Nicotiana benthamiana</i> Leaves: New Insights in Substrate Specificities with Relevance for Fabry DiseaseKassiani Kytidou, Thomas J M Beenakker, Lotte B Westerhof, et al.
BMC Pulmonary Medicine|March 23, 2018
IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomesAdrian Egli, Jyotshna Mandal, Desiree M Schumann, et al.
Chemical Science|November 30, 2023
<i>Trans</i>-cyclosulfamidate mannose-configured cyclitol allows isoform-dependent inhibition of GH47 α-d-mannosidases through a bump-hole strategyAlexandra Males, Ken Kok, Alba Nin-Hill, et al.
Pageof 37